Third quarter 2023 Results

Play to Win Financial levers
Q3 2023 earnings Financial performance
Business update Appendices

Q3 2023 Results
Play to Win
October 27, 2023

3
Forward-looking statements
Investor Relations
This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-
looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying
assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “potential”, “outlook”,
“guidance” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially
from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful,
the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to
complete capital markets or other transactions and/or obtain regulatory clearances, risks associated with developing standalone businesses,
risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in
exchange rates and prevailing interest rates, volatile economic and capital market conditions, cost containment initiatives and subsequent
changes thereto, and the impact that pandemics, political disruption or armed conflicts or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global
economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s
annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
Brand names appearing in this presentation are trademarks of Sanofi and/or its affiliates. Not all trademarks related to products under
development have been approved as of the date of this presentation by the relevant health authorities.

4
Agenda
Investor Relations
Q3 2023 earnings: Speciality
Care strong growth drives
portfolio transformation
Paul Hudson & Jean-Baptiste de Chatillon
Next chapter of Play to Win
Paul Hudson, Houman Ashrafian
& Julie Van Ongevalle
Financial levers to support
next phase of growth
Paul Hudson & Jean-Baptiste de Chatillon
01
03
02

5
Next chapter of Play to Win to drive long-term value
Investor Relations
1. Subject to market conditions and consultations with social partners.
Significantly stepping up
R&D investments
Bolstered by successful
launches and R&D
developments increasing
investments in pipeline
to fully realize long-term
growth potential
Intention to
separate CHC
At the earliest in Q4 2024 via
the creation of a publicly
listed entity headquartered
in Paris1
Enabling management
focus and resource allocation
to the needs of the
Biopharma business
Launch of strategic
cost initiatives
Targeting total up to €2bn
from 2024 to end of 2025,
to be reallocated in majority

Q3 2023 earnings:
Specialty Care strong
growth drives portfolio
transformation

7
Q3 2023: Strong growth of Specialty Care continues to drive
portfolio transformation towards innovative medicines
Investor Relations
All growth at CER unless footnoted. Growth rate is vs. Q3 2022.
Specialty Care
€4.6bn
+13.5%
GenMed
€3.0bn
-6.6%
Vaccines
€3.1bn
-0.6%
Core
assets
€1.5bn
+3.1%
€1.2bn
+4.6%
Consumer
Healthcare
• Q3 sales up 3.2%
• Double-digit growth of Speciality
Care driven by Dupixent and
Rare Diseases
• Vaccines: Beyfortus strong
uptake; Flu sales lower due to
U.S. market dynamics and
delayed shipments in RoW
• CHC growth from key categories
• GenMed core assets up; Non-core
decline due to continued pricing
headwinds

8
Significant blockbuster potential with key launches
Investor Relations
Barring unforeseen events. 1. At the end of Q3.
Protect all infants against RSV
in their first season
First and only therapy
to delay onset of T1 diabetes
Potential new standard in
protection with weekly dosing
Q3 execution highlights
~40% share of patient
switches in U.S.1, 650
+ patients on therapy
Strong ramp up in launch
markets U.S., France
and Spain
Growing number of patient
enrollments in the support
programs; 111 patients
infused to date
Combined
sales expectations
raised:
>€500m
in H2 2023

9
Dupixent continues impressive growth, annualizing >€11bn
Investor Relations
All growth at CER. 1. Represents growth Q3 2023 to Q3 2022. EADV: European Academy of Dermatology and Venereology.
Global Dupixent sales (€m)
U.S.
(+30%)1
Ex-U.S.
(+43%)1
455
725
1,061
1,803
115
193
349
511
683
Q3 ’19 Q3 ’20 Q3 ’21 Q3 ’22 Q3 ’23
570
918
1,410
2,314
2,847
2,164
750,000
patients
on therapy
globally
U.S. and EU AD
label updated
with adult 5yr
safety data
New
indications to
expand label
Leading
scientific
presence at
EADV

6
Influenza leadership driven by differentiated vaccines
in increasingly competitive markets
Investor Relations
Differentiated flu vaccines are Fluzone High Dose/Efluelda and Flublok/Supemtek.
Worldwide differentiated flu vaccines sales
Increased Efluelda penetration
in EU4 markets, with expansion
in additional EU markets
Vaccination coverage rates remain
below pre-pandemic level
Net price erosion on standard
dose vaccine
Key drivers of flu performance
485 392
600
888
49%
Q3
2018
53%
Q3
2019
56%
Q3
2020
66%
Q3
2021
65%
Q3
2022
71%
Q3
2023
1,301 1,249
Sanofi Sales in €m @published rate % of total Sanofi flu sales

11
Expanding immunology leadership with differentiated TL1A
candidate in promising class addressing IBD
Investor Relations
The transaction will become effective after customary closing conditions are met. Source: Crohn’s & Colitis Foundation, DRG Clarivate market report (2022), Evaluate Pharma (Q2-2023).
Large underserved market
10m
people WW with IBD
>4m
diagnosed patients
2.7m
treated
patients
>$28bn
2028 WW IBD
Market Sales
Patient population IBD market potential
Potential best-in-class anti-TL1A
profile with differentiated
antibody design
TL1A blockade is an emerging MOA in IBD
and beyond with anti-inflammatory and
anti-fibrotic activity
BIC potential due to greater in vitro potency
and selectivity for DR3 receptor
Favorable safety and tolerability, with
low anti-drug antibody
Collaboration with Teva

• 10M invasive ExPEC cases worldwide yearly2
• A leading cause of sepsis; high rates of
hospitalizations and mortality3
• Targeting all adults 60+, leveraging our
expertise to gain recommendation and funding
Blockbuster
potential
• Signed agreement with Janssen1
• Worldwide Phase 3 trial ongoing
• Solid addition to Older Adult vaccines portfolio
Strong
portfolio fit
12
First-in-class ExPEC vaccine candidate with excellent strategic fit
Investor Relations
Note: Closing is subject to customary regulatory clearance.
1. Sanofi Press Release 3rd Oct 23. 2. Russo TA and Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003;5:449–456.
3. Ohmagari et al., Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions. J Med Econ. 2023 Jan-Dec;26(1):168-178.

13
Solid financial performance despite Gx impact on Aubagio,
Sanofi’s last meaningful LoE in the decade
Investor Relations
1. Growth rates at CER. 2. At published rates.
13 Investor Relations
9M 2023 9M 2022 Change1
Sales €32.2bn €32.3bn +3.9%
Gross margin 74.8%2 74.3%2 +0.5pts2
R&D spend €4.9bn €4.9bn +1.6%
BOI margin 31.4% 32.0% -0.6pts2
Business EPS €6.45 €6.55 +4.9%

14
H2 2023 business outlook
Investor Relations
Barring unforeseen events. 1. ALTUVIIIO, Beyfortus and Tzield. 2. In Other Revenues, booked in Q4.
• Dupixent strong performance to continue
• High rate of Aubagio generic erosion coupled with entry of generics in Europe
• Flu sales split roughly 70/30 Q3 vs. Q4
• GenMed sales decline in the mid-single digit range
• New launches expected to generate sales of >€500m1
Sales
P&L
• Expected COVID vaccine one-off revenues of ~€400m2
• OPEX growth due to investments in launches and R&D; CHC stand-alone
• Capital gains from product divestments expected to reach approximately ~€200m
• Tax rate of 19%

15
FY 2023 guidance reaffirmed
Investor Relations
Barring unforeseen events. 1. Based on October 2023 average rates.
15
EPS growth
approximately
-6.0% to -7.0%
Currency
impact1
Mid single-digit
growth at CER

Next chapter of
Play to Win

17
Proof points of success propel next chapter of Play to Win
Investor Relations
Scaling Dupixent
to be among the
world’s leading
medicines
Developing an
industry-leading
immunology
pipeline
Building
a high-growth
vaccines
business
Streamlining
the portfolios
of GenMed
and CHC

18
Building on significant progress transforming R&D
over the past 4 years
Investor Relations
6 therapeutic areas
Broad range of
technology platforms
External innovation
International
R&D team
Deploying
AI, data science,
and computational
expertise throughout
the organization

Orals Injectables
Dermatology
AD IRAK4 degrader amlitelimab (anti-OX40L)
CSU rilzabrutinib (BTKi) Dupixent
HS IRAK4 degrader Anti-TNFa/OX40L Nanobody VHH
Psoriasis Oral TNF inhibitor
Respiratory
Asthma rilzabrutinib (BTKI) amlitelimab (anti-OX40L)
Anti-IL-13/TSLP Nanobody VHH
COPD Dupixent
itepekimab (anti-IL-33)
Gastroenterology
EoE Dupixent (pediatric)
EG Dupixent
UC eclitasertib (RIPK1i) Dupixent
non-beta IL-2 (Synthorin™)
Anti-TL1A mAb
CD Anti-TL1A mAb
Autoimmune
Lupus frexalimab (anti-CD40L)
Anti-CD38 mAb Next Generation
Endocrinology
T1D Tzield
frexalimab
19
Target to expand immunology leadership with new assets
in areas of high unmet need
Investor Relations
Barring unforeseen events. Pipeline table contains assets with indications still under investigation and not yet approved by any regulatory authority.
Leadership today
6m and older
Atopic Dermatitis
Asthma
CRSwNP
EoE
Prurigo Nodularis
Industry leading immunology pipeline

20
Amlitelimab shows significant improvements in signs
and symptoms of atopic dermatitis
Investor Relations
1. Data collected after early treatment discontinuation due to reasons other than lack of efficacy prior to endpoint timepoint are included. Data on or after rescue medication or prohibited medications impacting efficacy start date or after the date of treatment
discontinuation due to lack of efficacy prior to endpoint timepoint, were considered as non-responders. Any other unobserved values or other missing data are considered as non-responders at Week 16 and Week 24. 2. All data are used for analysis
regardless of treatment discontinuation, regardless of rescue/prohibited concomitant medications use. Missing data are considered as non-responders at Week 16/Week 24.
0%
10%
20%
30%
40%
50%
60%
70%
40.3
54.5
61.0
11.4
17.7
21.5
Percentage of patients achieving
EASI-75 at Weeks 16 and 24
0%
10%
20%
30%
40%
50%
Percentage of patients achieving
IGA 0/1 at Weeks 16 and 24
Patients
%
22.1
45.5
49.4
5.1
11.4 11.4
250mg
(with LD)
Placebo
Week 161 Week 241 Week 242
Proportion
difference
vs. placebo
(95% CI) p=0.0022
17
(6,27)
p<0.0001
34
(21,47)
p<0.0001
38
(25,51)
Results supporting the potential
for meaningful efficacy in patients with
moderate-to-severe atopic dermatitis
Most rapid and greatest continued
reduction through Week 24 in
Th2/Th17/Th22 biomarkers, suggesting
benefit of loading dose
Opportunity for reducing treatment
dosing frequency
Well-tolerated, with an absence of
fever/pyrexia, chills, and aphthous ulcers
Proportion
difference
vs. placebo
(95% CI)
29
(16,42)
36
(23,50)
39
(25,53)
Patients
%
All p<0.0001
250mg
(with LD)
Placebo

21
Avenues of future growth to be presented
at R&D Day on December 7
Investor Relations
Advancing R&D strategic transformation
Sustaining leadership with Dupixent in Type 2
Progressing transformative assets in Immuno-inflammation
and beyond
Leveraging differentiated technology platforms
Employing Artificial Intelligence at scale to accelerate
R&D productivity

22
We have built the foundations for CHC’s next phase
of growth as a publicly listed entity
Investor Relations
1. Boehringer Ingelheim. 2. Subject to markets conditions and consultations of social partners.
Today
2014 At the earliest in Q4 20242
2017 2020 end
BU
creation
Publicly
listed
entity
Ready
for next
step
Integration
of B.I.1
Brands
3 strategic
priorities
2023
• €3.3bn net sales
• Below market growth
• Encumbered by Pharma-specific processes
• Decentralized eCommerce & Digital Initiatives
• Inefficiencies due to large portfolio
• €5.2bn net sales
• Proven leadership team
• Brand-led organization
• Established manufacturing footprint
• Clear digital & IT roadmap
• Distinct sustainability commitment

23
CHC business reshaped for continued growth
Investor Relations
1. YTD Sep 2023 (excluding Qunol). 2. Excluding Qunol.
15 priority brands All brands with top-3 sales
positions in their respective
geographies, of which 11 are #1
Representing ~2/3
of total net sales1
Representing 85%
of 2019-2022 growth2

24
A CHC leader in the attractive OTC & VMS market
Investor Relations
Source: Company reports (OTC & VMS only). Other consumer care (“non-OTC & VMS”) categories include Personal care, Oral Care and Skin Care
OTC & VMS sales
2022, €bn
4.3
0.5
Haleon Kenvue Sanofi CHC Bayer P&G Reckitt Nestlé
4.8
Sanofi CHC
VMS
OTC

Financial levers
to support next
phase of growth

26
Play to Win strategy delivered on financial objectives
Investor Relations
1. 2018 proforma BOI margin of 24.6% without equity investment in Regeneron sold in May 2020, excluding IFRS16 impacts.
Cash flow
30%
BOI margin
10 consecutive quarters of growth
540bps BOI margin improvement
from 2019 to 20221
€2.7bn cost savings re-invested
in growth drivers
>25 value-creating BD and M&A deals
Accelerating digitalization
2020 - 2022
x2
vs. 2018

1
27
Capital allocation policy
unchanged
Investor Relations
Organic investment
2 M&A/business development
3 Growing dividend
4 Anti-dilutive share buybacks

28
Strengthening the pipeline through increased R&D investment
Investor Relations
2023 numbers will be reported on February 1, 2024. R&D spending 2024E is illustrative.
5.5 5.7
6.7 6.8
2020A 2021A 2022A 2023E 2024E
Continuous growth of absolute R&D spend
from 2020-2023, mainly driven by mRNA
Further increase in 2024 mainly due to
• Frexalimab Phase 3 program in MS
• Phase 3 vaccines programs starting
(PCV, RSV)
• Cost sharing of ExPEC program (JNJ)
• Amlitelimab Phase 3 start moved to 2024
(initially planned for 2023)
Upcoming end of Phase 3 in late 2024
or 2025 (Dupixent and itepekimab
COPD, tolebrutinib)
R&D spend in €bn

29
GenMed simplification progressing ahead of plan
Investor Relations
1. 2020 sales excluding third party Industrial Affairs sales.
Streamlining the number of branded product families
~300
2018 2020
H1 2020 YTD Sep
2021
2025E
Long
tail
~220
~180
~160
~100
YTD Sep
2023
~85
Target number of around 100 branded
product families set in 2019 reached two
years earlier than initially planned
Generated more than €1.9 billion of cash
proceeds from divestments 2019 to 2023
Streamlining to continue down to around
85 branded product families
Stabilizing sales in 2025 at the 20201
level no longer an objective

30
Launch of strategic cost initiatives, targeting total up to €2bn
from 2024 to end of 2025, to be reallocated in majority
Investor Relations
Priorities
In pursuit of first-in-class/best
in class pipeline assets, active
reallocation of pipeline
resources (i.e., from oncology
to immunology)
Smart
spending
Further leverage
procurement to generate
additional savings
Operational
excellence
Optimize country setup,
increase degree of
centralization by expanding
hub strategy, refocus
R&D infrastructures and
technology platforms
€0.7bn €0.6bn €0.7bn

+3.9%
31
Preliminary outlook 2024 and 2025
Investor Relations
At CER, barring unforeseen events.
• Continued sales growth supported by
leading franchises and launches
• Dupixent reaching close to €13bn
• Step up in R&D expenses
• Investing behind launches
• Tax rate of 21%
• Low single-digit EPS decline (roughly
stable at comparable tax rate)
Business EPS growth
Company sales growth
• Continued sales growth
supported by Dupixent, other
leading franchises and launches
• Full benefit from planned
efficiency initiatives and
its expectation of relatively
stable R&D expenses and
tax rate year-on-year
• Strong rebound in Business
EPS growth
+4.9%
2024 2025
2020 2022
2021 9M YTD 2023
2020 2022
2021 9M YTD 2023 2024 2025

32
Entering the next chapter of our Play to Win strategy
to drive long-term value
Investor Relations
Barring unforeseen events.
32
2020-2022 2023-2024 2025-2030
Consistent capital allocation policy
Refocus with
decisive actions
Growth through
winning assets
Margin expansion
Industry leader in immunology
with >€22bn sales by 2030
Vaccines sales >€10bn by 2030
Ambition to launch 3-5 new products
with €2-5bn peak sales potential each
Stepping up R&D
investment
Aubagio last major LoE,
accelerated GenMed
streamlining
Company
modernization

Q&A session

Business
update
Q3 2023

35
Specialty Care performance
Investor Relations
1. Rare Diseases includes Rare Blood Disorders. 2. Average market share in countries that have launched Nexviazyme as of Aug 23.
Dupixent
€2,847m
+32.8%
Rare Diseases1
€1,284m
+12.1%
€4.6bn sales +13.5%
Neurology,
Oncology &
Rheumatology
€504m
-37.0%
Dupixent
Strong demand-driven growth across all
geographies and approved indications
Rare Diseases
• Nexviazyme average switch rate exceeds 70%2
• Double-digit growth in Fabry franchise, mainly
due to patient accruals
• Hemophilia franchise up in both Hem A and B,
driven by ALTUVIIIO and Alprolix, respectively
• Aubagio LoE sales erosion with full quarter
of U.S. Generics; EU Generics launched
in late Q3
Q3 2023

Booster
vaccines
€185m
+10.1%
Meningitis
Travel &
Endemic
€409m
-7.6%
36
Vaccines performance
Investor Relations
Polio/Pertussis/Hib
€577m
-3.4%
Influenza
€1,766m
-6.2%
Others
€24m
-10.3%
€3.1bn -0.6%
sales
Outstanding Beyfortus uptake across U.S.,
Spain and France with “All Infant Protection”
programs
Higher sales from differentiated influenza
vaccines, offset by declining vaccination rates,
increased competition in the U.S. and delayed
shipments in RoW
Meningitis franchise sales driven by
CDC order pattern
Beyfortus
€137m
Q3 2023

Core assets
€1,512m
+3.1%
37
GenMed performance
Investor Relations
€3.0bn -6.6%
sales
Industrial
sales
€126m
+2.4%
Non-core
assets
€1,348m
-16.0%
Core assets
Double-digit growth of Rezurock,
Thymoglobulin and Praluent
Lovenox decline as anticipated; lower
Toujeo sales due to U.S. net pricing
Progressive ramp-up of Tzield
Non-core assets
Lantus impacted by significant U.S. net price
decline due to unfavorable channel mix
Portfolio streamlining
Net Impact on sales: -2.2ppt
Q3 2023

38
CHC performance
Investor Relations
All growth at CER. Growth rate is vs. Q3 2022. Organic growth: Excluding impacts of divestments & acquisitions.
€1.2bn sales +4.6%
Physical
& Mental
Wellness
€127m
-4.2%
Others
€173m
-6.5%
Cough & Cold
€131m
+7.9%
Digestive Wellness
€366m
+8.0%
Allergy
€176m
+14.1%
Pain Care
€272m
+5.1%
10th consecutive growth quarter
Growth primarily from price, with volume
maintained at post post-pandemic high base
Digestive Wellness continues to perform
Allergy and Pain Care back to growth, driven by
Allegra worldwide and Eve in Japan, respectively
Q3 organic growth +6.3%
Q3 2023

Positive drivers of
continued launch execution
90% of U.S. HCPs anticipate
increasing ALTUVIIIO usage
in next 12 months
Permanent J-code available
since October 1, 2023, facilitates
reimbursement
Global expansion with regulatory
approvals in Japan and Taiwan
39
ALTUVIIIO: Best-In-Disease efficacy profile drives strong
Q3 uptake
Investor Relations
1. 2018 proforma BOI margin of 24.6% without equity investment in Regeneron sold in May 2020, excluding IFRS16 impacts.
650+
Patients
with TRx
More than
doubled
total number
of patients
with Rx vs. Q2
#1
Switched
to factor
ALTUVIIIO
captures 40%
of all switches in
hem A market
at the end of Q3
90%
Conversion
rate
% of patients
converting to
commercial
supply post
free trial program

Record speed to
make Beyfortus
available in the U.S.
• 8 weeks from license
approval to first shipments
in September
• Ad hoc ACIP meeting 3 weeks
post-license with unanimous
vote for All Infant Protection
and VFC inclusion
• Insurance coverage secured
for ~90% of U.S. lives as
of October 1
40
Beyfortus: Unprecedented demand at launch
Investor Relations
Barring unforeseen events.
Rapid adoption immediately
after launch
Launched on September 15
>60% immunization rate
among newborns in hospitals
14 out of 17 regions launched
in the last week of September/
first week of October
>50% immunization rate
of babies in select regions

41
GenMed Q3 2023 core assets performance
Investor Relations
All growth at CER unless footnoted.
Core asset sales (in € million)
307 304
230
246
101
83
54
255 265
218
257
93
115
50
-9.8% -4.9%
+5.2%
+12.6%
-1.0% +44.6%
+1.9%
Q3 2022 Q3 2023

Financial
performance
Q3 2023

43
Q3 Group P&L
Investor Relations
All growth at CER. 1. Margin at published rate.
43
Sales growth
+3.2%
Gross margin
-0.6ppt decrease
driven by currency
BOI
-1.0% driven by Aubagio
LoE, unfavorable flu phasing
and unfavorable base of
comparison for the Regeneron
mAbs collaboration
EPS
-2.1% decrease driven
by lower BOI and higher
net financial charges
€m Q3 2023 Q3 2022 % Change
Net Sales 11,964 12,482 +3.2%
Other revenues 734 656 +23.2%
Gross profit 8,858 9,307 +3.5%
Gross margin % 74.0%1 74.6%1
R&D (1,663) (1,736) +0.9%
SG&A (2,579) (2,644) +4.6%
Operating Expenses (4,242) (4,380) +3.1%
Other current operating income & expenses (598) (450) +49.3%
Business Operating Income 4,028 4,498 -1.0%
Business operating margin 33.7%1 36.0%1
Effective tax rate 19% 19%
Total Business Net Income 3,196 3,606 -1.9%
Average number of shares 1,253.2 1,253.5
Business EPS 2.55 2.88 -2.1%

44
Q3 CHC P&L
Investor Relations
All growth at CER. 1. Margin at published rate.
44
€m Q3 2023 Q3 2022 % Change
Net Sales 1,245 1,300 +4.6%
Other revenues 11 16 -25.0%
Gross profit 754 829 +1.1%
Gross margin % 60.6%1 63.8%1
R&D (52) (54) +1.9%
SG&A (419) (432) +3.2%
Operating Expenses (471) (486) +3.1%
Other current operating income & expenses (3) (4)
Business Operating Income 284 337 +0.9%
Sales growth
+4.6% driven due to
Digestive Wellness & Allergy
SG&A
+3.2% driven by
investment in stand-alone
organization
BOI margin
reflects Fx impact, lower
gross margin ratio due to
unfavorable mix effect
and inflation impact on
cost of sales

45
9M P&L
Investor Relations
All growth at CER unless footnoted. 1. Margin at published rate.
€m 9M 2023 9M 2022 % Change (CER)
Net Sales 32,151 32,272 +3.9%
Other revenues 2,092 1,661 +32.0%
Gross profit 24,061 23,975 +4.9%
Gross margin % 74.8%1 74.3%1
R&D (4,856) (4,883) +1.6%
SG&A (7,761) (7,597) +5.7%
Operating Expenses (12,617) (12,480) +4.1%
Other current operating income & expenses (1,403) (1,238) +19.5%
Business Operating Income 10,087 10,316 +4.1%
Effective tax rate 19.0% 19.0%
Total Business Net Income 8,072 8,200 +4.8%
Average number of shares 1,251.0 1,251.2
Business EPS 6.45 6.55 +4.9%

46
Main product sales
Investor Relations
All growth at CER unless footnoted.
Q3 2023 sales (€m) Growth
Dupixent 2,847 32.8%
Influenza vaccines 1,766 -6.2%
Polio/Pertussis/Hib vaccines 577 -3.4%
Meningitis, Travel and Endemic vaccines 409 -7.6%
Lantus 343 -32.9%
Toujeo 265 -4.9%
Lovenox 255 -9.8%
Fabrazyme 253 14.2%
Plavix 218 5.2%
Aubagio 199 -60.5%
Myozyme 187 -22.4%
Booster vaccines 185 10.1%
Cerezyme 176 7.2%
Allergy 176 14.1%
Alprolix 138 19.8%
Beyfortus 137 -
Thymoglobulin 123 15.3%
Eloctate 120 -13.2%
Praluent 115 44.6%

nirsevimab/Beyfortus
Initial agreement Sanofi-AstraZeneca (March 2017)
Major markets (U.S., FR, DE, ES, IT, UK, JP) Rest of world markets
Net sales Sanofi consolidates worldwide net sales
Cost of sales Sanofi consolidates worldwide cost of sales (finished goods purchased from AstraZeneca)
R&D AstraZeneca & Sanofi share the alliance development costs 50/50
SG&A
Sanofi expenses 100% of its SG&A (and further shares 50/50
in OOIE)
Sanofi expenses 100% of its SG&A
(not shared)
Other operating
income and expenses
Alliance
profit & loss
Sanofi shares with AstraZeneca the alliance commercial
profit & loss 50/50
Sanofi pays to AstraZeneca
25% of net revenues
Intangible asset
Beyfortus
(amortized below
BNI over useful life)
Upfront EUR 120M paid by Sanofi to AstraZeneca upon closing (March 2017)
Regulatory
milestones
AstraZeneca received from Sanofi EUR 55M and will receive EUR 65M for BLA Approval in the U.S.
Sales
milestones
AstraZeneca to receive up to EUR 375M sales milestones from Sanofi, upon achievement of certain sales related milestones
Above BNI Below BNI

Sanofi accounting of nirsevimab/Beyfortus
Updated and new agreements Sanofi-AstraZeneca and Sanofi-Sobi (October 2023)
U.S. Major markets (CN, FR, DE, ES, IT, UK, JP) Rest of world markets
Net sales Sanofi consolidates worldwide net sales
Cost of sales Sanofi consolidates worldwide cost of sales (finished goods purchased from AstraZeneca)
R&D Sanofi bears 100% of the costs from April 2023 onward AstraZeneca & Sanofi share the alliance development costs
SG&A Sanofi bears 100% of the costs from April 2023 onward Sanofi expenses 100% of its SG&A
(and further shares 50/50 in OOIE)
Sanofi expenses 100% of
its SG&A (not shared)
Other
operating
income and
expenses
Alliance profit
& loss
Sanofi consolidates 100% of the economics in the U.S.
from April 2023 onward
Sanofi shares with AstraZeneca the alliance
commercial profit & loss 50/50
Sanofi pays to AstraZeneca
25% of net revenues
Intangible
asset
Beyfortus
(amortized
below BNI
over useful
life)
Upfront EUR 120M paid by Sanofi to AstraZeneca upon closing (March 2017)
Regulatory milestones AstraZeneca received from Sanofi EUR 120M
Sales milestones AstraZeneca to receive up to EUR 375M sales milestones from Sanofi, upon achievement of certain sales related milestones
Additional rights
from AstraZeneca
(amendment April 2023)
Sanofi records price of U.S rights to obtain full commercial control (Fair Value)
Royalty Agreement Sanofi–Sobi (April 2023)
Financial liability (Sobi) Initial recognition at Fair Value of U.S. royalties due to Sobi - Liability reduced by royalty payments over time -
Subsequent re-measurement in P&L below BNI
Updated agreement Sanofi-AstraZeneca
Above BNI Below BNI

Q3 sales and EPS
Currency impact
Company sales Business EPS
€661m
€1,108m
€475m
€16m
€-484m
€-922m
+0.12
2022
Q2
+0.31
Q3 Q4
+0.09
Q1
2023
Q2
-0.01
Q3
-0.13
-0.27
2022
Q2 Q3 Q4 Q1
2023
Q2 Q3

1. Credit ratings reaffirmed: Moody’s A1/stable, S&P AA/stable, Scope AA/stable as of September 30, 2023. 2. Including derivatives used to manage net debt: €142m at December 31, 2022, and €247m at September 30, 2023.
3. Effective January 1, 2019, net debt does not include lease liabilities following the first-time application of IFRS16. 4. Including €363m use of funds from acquisition of treasury shares, -€187m of issuance of Sanofi shares and €577m of other items.
884
3,915
753
6,437
-820
4,454
667
Dividends paid
to shareholders
of Sanofi
10,577
-5,713
Net Debt
December 31,
20222,3
Net Debt
October 27,
20232,3
FCF before
restructuring,
acquisitions
& disposals
Proceeds
from
disposals
Asset
acquisition
Restructuring
& similar
items
Other4
Net debt evolution in 9M 20231
€ millions
Acquisitions of
investments in
consolidated
undertakings

2023 currency sensitivity and Q3 2023 currency exposure
US $ 48.2%
Euro € 19.7%
Chinese Yuan 5.6%
Japanese Yen 3.1%
Brazilian Real 1.9%
Mexican pesos 1.7%
Canadian $ 1.6%
Turkish Lira 1.4%
Australian $ 1.1%
South Korean won 1.1%
Others 14.6%
Currency exposure on Q3 2023 sales
2023 Business EPS currency sensitivity
Currency Variation Business EPS sensitivity
U.S. Dollar + 0.05 USD/EUR - EUR 0.17
Japanese Yen + 5 JPY/EUR - EUR 0.02
Chinese Yuan + 0.2 CNY/EUR - EUR 0.03
Brazilian Real + 0.4 BRL/EUR - EUR 0.02
Russian Ruble + 10 RUB/EUR - EUR 0.02
Currency average rates
Q3 2022 Q3 2023 % change
EUR/USD 1.007 1.088 +8.1%
EUR/JPY 139.332 157.211 +12.8%
EUR/CNY 6.909 7.896 +14.3%
EUR/BRL 5.289 5.311 +0.4%
EUR/RUB 60.008 102.548 +70.9%

R&D
appendices
ESG appendices Abbreviations Collaborations
R&D appendices

H1 2023 H2 2023
Dupixent
COPD
Positive pivotal trial readout
(BOREAS)
CIndU Efficacy criteria not met
Oncology
Sarclisa (1L MM, IMROZ) Pivotal trial readout (IMROZ)
tusamitamab ravtansine (LC03) Interim analysis
Neurology tolebrutinib Moved to mid-2024 (event-driven)
Rare Blood Disorders
fitusiran (Hem A/B)
Positive pivotal trial readout,
U.S. submission planned in 2024
ALTUVIIIO (Hem A) U.S. approval
Vaccines Beyfortus U.S. approval
As of September 30, 2023, barring unforeseen events. For abbreviations see slide 64.
Major R&D milestones in 2023
R&D appendices

As of September 30, 2023. For abbreviations see slide 64. For collaborations see slide 65.
R&D Pipeline Phase III & Registration
Name Description Indication
DupixentA
Anti-IL-4/IL-13 mAb Chronic Obstructive Pulmonary Disease
DupixentA Anti-IL-4/IL-13 mAb Bullous Pemphigoid
DupixentA Anti-IL-4/IL-13 mAb Chronic Pruritus of Unknown Origin
itepekimabA Anti-IL-33 mAb Chronic Obstructive Pulmonary Disease
TZIELD Anti-CD3 mAb Type 1 Diabetes
Sarclisa Anti-CD38 mAb + combinations 1L Newly Diag. MM Ti (IMROZ)
Sarclisa Anti-CD38 mAb + combinations 1L Newly Diag. MM Te (GMMG)
Sarclisa Anti-CD38 mAb + combinations Smoldering MM (ITHACA)
Sarclisa Anti-CD38 mAb SubQ. + combinations 2/3L Relapsed, Refractory MM (IRAKLIA)
tusamitamab ravtansine Anti-CEACAM5 ADC 2/3L NSCLC
tolebrutinib BTK inhibitor Relapsing Multiple Sclerosis
tolebrutinib BTK inhibitor Primary Progressive MS
tolebrutinib BTK inhibitor Secondary Progressive MS
Nexviazyme Enzyme Replacement Therapy (GAA) Pompe Disease - Infantile Onset
venglustat Oral GCS inhibitor GM2 Gangliosidosis
venglustat Oral GCS inhibitor Gaucher Disease Type 3
venglustat Oral GCS inhibitor Fabry Disease
fitusiran RNAi targeting anti-thrombin Hemophilia A and B
fitusiran RNAi targeting anti-thrombin Hemophilia A and B pediatric
rilzabrutinib BTK inhibitor Immune Thrombocytopenia
MenQuadfi Meningococcal (A,C,Y,W) conjugate vaccine Meningitis 6w+ (U.S./EU)
VRVg Purified vero rabies Vaccine Rabies
DupixentA
Anti-IL-4/IL-13 mAb Chronic Spontaneous Urticaria
Phase III Registration
Immuno-inflammation
Oncology
Neurology
Rare Diseases
Vaccines
R&D appendices

1. Also known as SAR445229. 2. Also known as SAR443122/DNL758. 3. Also known as SAR441344. 4. Also known as KT474. 5. Also known as DNL788. 6. Also known as SP0178. NANOBODY is a trademark of Sanofi and affiliates.
R&D Pipeline – Phase II
Phase II
frexalimabC,3
Anti-CD40L mAb Multiple Sclerosis
SAR445088 Complement C1s inhibitor CIDP
SAR443820B,5 RIPK1 inhibitor Amyotrophic Lateral Sclerosis
SAR443820B,5
RIPK1 inhibitor Multiple Sclerosis
rilzabrutinib BTK inhibitor
Warm Autoimmune Hemolytic
Anemia
SAR445088 Complement C1s inhibitor Cold Agglutinin Disease
Fluzone HD6
Inactivated Influenza Vaccine (IIV) Pediatric Influenza
SP0218 Vero cell Vaccine Yellow fever
SP0202D
Next Generation Conjugate Vaccine Pneumococcal
SP0125 Live Attenuated Virus Vaccine RSV toddler
SP0230 Multicomponent Vaccine Meningitis B
Immuno-inflammation
Oncology
Neurology
Rare Diseases
Vaccines
R Registrational Study (other than Phase 3)
DupixentA
Anti-IL-4/IL-13 mAb Ulcerative Colitis
R KevzaraA Anti-IL-6 mAb
Polyarticular Juvenile Idiopathic
Arthritis
R KevzaraA
Anti-IL-6 mAb Systemic Juvenile Arthritis
amlitelimab1 Anti-OX40L mAb Atopic Dermatitis
amlitelimab1 Anti-OX40L mAb Asthma
rilzabrutinib BTK inhibitor IgG4-related disease
rilzabrutinib BTK inhibitor Asthma
rilzabrutinib BTK inhibitor Chronic Spontaneous Urticaria
eclitasertibB,2 RIPK1 inhibitor Ulcerative Colitis
frexalimabC,3 Anti-CD40L mAb Sjogren’s Syndrome
frexalimabC,3 Anti-CD40L mAb Systemic Lupus Erythematosus
SAR445088 Complement C1s inhibitor Antibody-Mediated Rejection
SAR444656E,4
IRAK4 degrader Hidradenitis Suppurativa
SAR444656E,4 IRAK4 degrader Atopic Dermatitis
SAR442970 Anti-TNFa/OX40L Nanobody VHH® Hidradenitis Suppurativa
Sarclisa Anti-CD38 mAb 1/2L AML/ALL pediatrics
Sarclisa Anti-CD38 mAb + combinations Relapsed, Refractory MM
tusamitamab ravtansine Anti-CEACAM5 ADC + ramucirumab 2/3L NSCLC
tusamitamab ravtansine Anti-CEACAM5 ADC Exploratory Solid tumors
tusamitamab ravtansine Anti-CEACAM5 ADC + pembrolizumab 1L NSCLC
tusamitamab ravtansine Anti-CEACAM5 ADC + ramucirumab Gastric cancer
R&D appendices

1. Also known as KDS1001. 2. Also known as KD033. 3. Also known as KD050. 4. Also known as AMX-818. 5. Also known as SAR444245/THOR707. 6. Also known as ABL301. NANOBODY is a trademark of Sanofi and affiliates.
R&D Pipeline – Phase I
Phase I
SAR441566 TNFR1 signaling inhibitor Psoriasis
SAR443765 Anti-IL-13/TSLP Nanobody VHH® Asthma
SAR444336 Non-beta IL-2 Synthorin Inflammatory indication
SAR444559 Anti-CD38 mAb Next Generation Inflammatory indication
SAR445611 Anti-CX3CR1 Nanobody VHH® Inflammatory indication
SAR445399 Anti-IL1R3 mAb Inflammatory indication
SAR442257 CD38/CD28/CD3 T-Cell engager MM / N-H Lymphoma
SAR444881F
Anti-ILT2 mAb Solid tumors
SAR4454191 NK-Cell-based immunotherapy Acute Myeloid Leukemia
SAR443216 CD3/CD28/HER2 T-Cell engager Gastric cancer
SAR4457102 Anti-PDL1/IL-15 fusion protein Solid tumors
SAR4458773
Anti-PD1/IL-15 fusion protein Solid tumors
SAR443579G Trifunctional anti-CD123 NK-Cell engager Acute Myeloid Leukemia
SAR445514G Trifunctional anti-BCMA NK-Cell engager Relapsed, Refractory MM
SAR4463094
HER2 T-Cell engager Solid tumors
SAR444200 Anti-GPC3/TCR Nanobody VHH®
Solid tumors
pegenzileukin5 Non-alpha IL-2 Synthorin (dose optimization) Solid tumors
SAR446159H,6 Anti-Synuclein/IGF1R mAb Parkinson’s disease
SAR442501 Anti-FGFR3 Ab Achondroplasia
SAR443809 Anti-Factor Bb mAb Rare renal diseases
SAR439459 Anti-TGFb mAb Osteogenesis Imperfecta
SAR444836I
PAH replacement AAV-based gene therapy Phenylketonuria
SP0273 mRNA QIV Influenza
SP0256 mRNA RSV RSV older adults
Immuno-inflammation
Oncology
Neurology
Rare Diseases
Vaccines
R Registrational Study (other than Phase 3)
R&D appendices

2023
KevzaraA
Polyarticular juvenile idiopathic arthritis
2025 and beyond
DupixentA
CPUO
Nexviazyme
Pompe Disease - Infantile Onset
DupixentA
Bullous pemphigoid
venglustat
Gaucher Type 3
KevzaraA
Systemic Juvenile Arthritis
venglustat
Fabry Disease
amlitelimab
Atopic Dermatitis
fitusiran
Hemophilia A/B ped
itepekimabA
COPD
VRVg
Purified vero rabies vaccine
Sarclisa
Smoldering MM
SP0125
RSV toddler
Sarclisa SubQ
3L RR MM (IRAKLIA)
SP0202
Pneumococcal
tolebrutinib
PPMS
SP0218
Yellow fever
frexalimab
MS
Excluding Phase 1 and 2 (without Proof of Commercial Concept); Projects within a specified year are not arranged by submission timing.
Expected submission timelines
Immuno-inflammation
Oncology
Neurology
Rare Diseases
Vaccines
2024
DupixentA
COPD
tolebrutinib
SPMS
Sarclisa
1L Newly Diag. MM Ti (IMROZ)
venglustat
GM2 gangliosidosis
Sarclisa
1L Newly Diag. MM Te (GMMG)
rilzabrutinib
ITP
tusamitamab ravtansine
2/3L NSCLC
fitusiran
Hemophilia A/B
tolebrutinib
RMS
MenQuadfi
6w+
R&D appendices

ESG
appendices
R&D appendices

Figures presented are YTD.
Sanofi ESG Q3 achievements
Ambition Progress
Q3 2023 Q2 2023
Sanofi
Global Health
Reach 1.5 million NCD patients
by 2026 (cumulative since 2022)
and 2 million by 2030
176,473 patients treated in
27 countries
27 active healthcare partnerships in
14 countries
1 investment
123,025 patients treated
in 24 countries
25 active healthcare
partnerships in 12
countries
1 investment
Vials
donations
Donate 100,000 vials a year to
treat people with rare diseases, via
the Humanitarian Program launched
by Sanofi Specialty Care
74,083 vials donated
52,407 vials donated
Global
access plans
Develop a Global access plan
for all new products to make
them available within two years
after first launch
8 Global Access plans initiated or
developed covering more than 12
indications
6 Global Access plans
initiated or developed
covering more than
10 indications
Affordable access
R&D appendices

Ambition Progress
Q3 2023 Q2 2023
Sleeping
sickness
Develop and supply innovative
treatments to support the
elimination of sleeping sickness
by 2030
Data updated annually, next update
in Q2 2024
1.5 million
patients tested in 2022
837 patients treated
in 2022
Polio Provide inactivated polio vaccines
(IPV) to UNICEF for GAVI countries
to support polio eradication efforts
23.7 million IPV doses supplied
to UNICEF for GAVI countries
18.8 million IPV doses
supplied to UNICEF for
GAVI countries
Pediatric cancer
treatment
development
Develop innovative treatments to
eliminate cancer death in children
2 assets in protocol preparation
for clinical study
2 external collaboration
contracts with the pediatric ITCC
consortium established
2 assets in protocol
preparation for
clinical study
2 external collaboration
contracts with the
pediatric ITCC consortium
established
R&D for unmet needs
R&D appendices

Ambition Progress
Q3 2023 Q2 2023
Climate change -
carbon footprint
CO2 emissions
55% reduction in scope 1&2
greenhouse gas emissions (CO2
equivalent) by 2030 (cumulative
vs. 2019 baseline) to contribute to
carbon neutrality by 2030 and net
zero emissions by 2045 (all scopes)
35.0% GHG reduction
vs 2019
32.6% GHG
reduction vs. 2019
Renewable
electricity
100% of renewable electricity
in all our sites by 2030
72.0% 67.2%
Eco-car
fleet
100% carbon neutral
car fleet in 2030
39.8% eco fleet 36.5% eco fleet
Blister free syringe
vaccines
100% blister free syringe vaccines
by 2027(updated annually)
Data updated annually, next update
in Q4 2023
33% of blister free
syringe produced in 2022
Eco-design All new products to be
eco-designed by 2025
8 LCAs completed &
7 in progress (new and
marketed products)
7 LCAs completed &
4 in progress (new and
marketed products)
Planet Care
R&D appendices

Ambition Progress
Q3 2023 Q2 2023
Gender
balance
Ambition of 50% of women in
senior leaders by 2025
43.3% 42.4%
Ambition of 40% of women in
executive posts by 2025
39.3% 38.0%
Engagement with
communities
Engage socially and economically
with all communities where we
operate
5,905 volunteers
36,746 hours
2,883 volunteers
18,103 hours
From Leaders
to Citizens
100% of Sanofi leaders have
CSR in their development path
69% of the leaders have
completed the eLearning phase
18% of the leaders have
completed the full program
68% of the leaders
have completed the
eLearning phase
12% of the leaders
have completed the
full program
In and beyond the workplace
R&D appendices

Scores assigned by the rating agencies are not equivalent.
Sanofi ESG ratings
Rating agencies
SCORE
87/100
21.5
Medium risk
78/100 A
Climate
Change: A
Water: A-
B 4.5/5 3.47/5 65/100
86/100 21.2 71/100 A A/A B 4.3/5 3.47/5 64/100
One of the highest
scores across all
sectors globally
81 points for its
solid fundamentals
& strong
preparedness
opinion of
6 points
17th among 419
pharmaceutical
companies
Percentile of 98
within 344 scored
companies in the
industry
Score stable
since 2021
Leading position 1st decile of the
476 companies in
the industry
With very high
rating across the
3 pillars ESG
Top 10
company
1st pharmaceutical
company out of 57
Score improving
since 2018
vs. previous rating
R&D appendices

Abbreviations
AAV Adeno-Associated Virus
Ab Antibody
AD Atopic Dermatitis
ADC Antibody Drug Conjugate
ALL Acute Lymphoblastic Leukemia
AML Acute Myeloid Leukemia
BCMA B-Cell Maturation Antigen
BTK Bruton’s Tyrosine Kinase
CD Cluster of Differentiation
CD Crohn’s Disease
CEACAM5 Carcinoembryonic Antigen Cell Adhesion
Molecule 5
CI Confidence Interval
CIDP Chronic Inflammatory Demyelinating
Polyneuropathy
CInDU Chronic Inducible Cold Urticaria
COPD Chronic Obstructive Pulmonary Disease
CPUO Chronic Pruritus of Unknown Origin
CSR Corporate Social Responsibility
CSU Chronic Spontaneous Urticaria
DR3 Death Receptor 3
EASI Eczema Area and Severity Index
EG Eosinophilic Gastritis
EoE Eosinophilic Esophagitis
ExPEC Extraintestinal pathogenic E. coli
FGFR3 Fibroblast Growth Factor Receptor 3
GAA Acid Alpha-Glucosidase
GCS Glucosylceramide Synthase
GHG Greenhouse Gas
GPC3 Glypican-3
HD High Dose
HS Hidradenitis Suppurativa
HER2 Human Epidermal growth factor Receptor 2
IA Interim analysis
IBD Inflammatory Bowel Disease
IED Invasive ExPEC Disease
IGA Investigator Global Assessment
IGF1R Insulin Like Growth Factor 1 Receptor
IL Interleukin
ILT2 Ig-like transcript 2
IPV Inactivated Poliomyelitis Vaccine
IRAK4 Interleukin 1 Receptor Associated Kinase 4
ITCC Innovative Therapies for Children
with Cancer
ITP Immune Thrombocytopenia
LCA Life Cycle Assessment
LD Loading Dose
LoE Loss of Exclusivity
LRTD Lower Respiratory Tract Diseases
mAb monoclonal Antibody
MM Multiple Myeloma
mRNA messenger RNA
MS Multiple Sclerosis
NCD Non-Communicable Diseases
NGO Non-Governmental Organizations
N-H Non-Hodgkin
NK Natural Killer
NSCLC Non-Small Cell Lung Cancer
PAH Phenylalanine Hydroxylase
PD-1 Programmed Death protein 1
PD-L1 Programmed Death ligand 1
PN Prurigo Nodularis
PPMS Primary Progressive Multiple Sclerosis
PP-NRS Peak-Pruritus Numerical Rating Scale
QIV Quadrivalent Influenza Vaccine
RIPK1 Receptor-Interacting serine/threonine-
Protein Kinase 1
RMS Relapsing Multiple Sclerosis
RNAi RNA interference
RRMM Relapsed-Refractory Multiple Myeloma
RSV Respiratory Syncytial Virus
SPMS Secondary-Progressive Multiple Sclerosis
TCR T Cell Receptor
Te Transplant eligible
TGFb Transforming Growth Factor beta
Th Helper T-Cell
Ti Transplant ineligible
TL1A TNF-like Ligand 1A
TNF Tumor Necrosis Factor
TSLP Thymic Stromal Lymphopoietin
T1D Type 1 Diabetes
UC Ulcerative Colitis
VBP Volume-based Procurement
VFC Vaccines for Children
R&D appendices

Collaborations
Ref Name Developed in collaboration with…
A Dupixent
itepekimab
Kevzara
Regeneron
B eclitasertib
SAR443820
Denali
C frexalimab ImmuNext
D SP0202 SK
E SAR444656 Kymera
F SAR444881 Biond Biologics
G SAR443579
SAR445514
Innate Pharma
H SAR446159 ABL Bio
I SAR444836 Medicinova, Inc
TEV’574 Teva Pharmaceuticals
ExPEC9V Vaccine Janssen Pharmaceuticals, Inc., a Johnson & Johnson company
R&D appendices

Third quarter 2023 Results

Related slideshows

More Related Content

What's hot

What's hot (20)

Similar to Third quarter 2023 Results

Similar to Third quarter 2023 Results (20)

More from Sanofi

More from Sanofi (14)

Recently uploaded

Recently uploaded (20)

Third quarter 2023 Results